Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Special Reviews

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

Web of Science 38 Crossref 43

DOI: https://doi.org/10.3350/cmh.2023.0277

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

Web of Science 18 Crossref 23

DOI: https://doi.org/10.3350/cmh.2023.0291

Reviews

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka

Clin Mol Hepatol. 2023;29(4):851-868. Published online March 9, 2023

Web of Science 15 Crossref 13

DOI: https://doi.org/10.3350/cmh.2022.0434

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

Web of Science 6 Crossref 11

DOI: https://doi.org/10.3350/cmh.2022.0420

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clin Mol Hepatol. 2023;29(4):891-908. Published online April 13, 2023

Web of Science 5 Crossref 7

DOI: https://doi.org/10.3350/cmh.2023.0024

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(4):909-923. Published online May 25, 2023

Web of Science 11 Crossref 12

DOI: https://doi.org/10.3350/cmh.2023.0114

Evidence-based hyponatremia management in liver disease

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):924-944. Published online June 5, 2023

Web of Science 6 Crossref 6

DOI: https://doi.org/10.3350/cmh.2023.0090

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma

Hwa Kyung Byun, Changhwan Kim, Jinsil Seong

Clin Mol Hepatol. 2023;29(4):945-957. Published online August 14, 2023

Web of Science 6 Crossref 7

DOI: https://doi.org/10.3350/cmh.2023.0217

Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma

Sung Uk Lee, Tae Hyun Kim

Clin Mol Hepatol. 2023;29(4):958-968. Published online August 29, 2023

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2023.0274

Editorials

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

Web of Science 9 Crossref 8

DOI: https://doi.org/10.3350/cmh.2023.0359

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

Web of Science 6 Crossref 6

DOI: https://doi.org/10.3350/cmh.2023.0367

Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy

Sang Min Yoon

Clin Mol Hepatol. 2023;29(4):977-979. Published online August 31, 2023

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2023.0336

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?

Eugene Han, Yong-ho Lee

Clin Mol Hepatol. 2023;29(4):980-983. Published online August 16, 2023

Web of Science 2 Crossref 3

DOI: https://doi.org/10.3350/cmh.2023.0250

Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?

Hyo-Cheol Kim

Clin Mol Hepatol. 2023;29(4):984-986. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0275

Original Articles

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Clin Mol Hepatol. 2023;29(4):987-1001. Published online July 5, 2023

Web of Science 15 Crossref 18

DOI: https://doi.org/10.3350/cmh.2023.0035

Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study

Vy H. Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(4):1002-1012. Published online September 11, 2023

Web of Science 8 Crossref 9

DOI: https://doi.org/10.3350/cmh.2023.0205

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Clin Mol Hepatol. 2023;29(4):1013-1028. Published online July 5, 2023

Web of Science 3 Crossref 3

DOI: https://doi.org/10.3350/cmh.2023.0131

Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon

Clin Mol Hepatol. 2023;29(4):1029-1042. Published online August 29, 2023

Web of Science 4 Crossref 4

DOI: https://doi.org/10.3350/cmh.2023.0190

Letters to the Editor

Letter regarding “Evidence-based hyponatremia management in liver disease”

Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos

Clin Mol Hepatol. 2023;29(4):1043-1045. Published online July 5, 2023

Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0204

Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh

Clin Mol Hepatol. 2023;29(4):1046-1047. Published online August 22, 2023

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0268

Correspondences

Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):1048-1049. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0261 Correction in: Clin Mol Hepatol 2024;30(1):134

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):1050-1051. Published online August 29, 2023

Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0310

Snapshot

The role of the hepatic autonomic nervous system

Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin

Clin Mol Hepatol. 2023;29(4):1052-1055. Published online July 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0244

Viewed By 5060	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 5024	MAFLD: How is it different from NAFLD?
Viewed By 4464	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4423	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4340	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues